Literature DB >> 31816060

Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor.

Margaret Nieborowska-Skorska1, Elisabeth M Paietta2, Ross L Levine3, Hugo F Fernandez4, Martin S Tallman3, Mark R Litzow5, Tomasz Skorski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31816060      PMCID： PMC6963253          DOI： 10.1182/bloodadvances.2019000756

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  22 in total

1.  Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Authors:  Friederike Christen; Kaja Hoyer; Kenichi Yoshida; Hsin-An Hou; Nils Waldhueter; Michael Heuser; Robert K Hills; Willy Chan; Raphael Hablesreiter; Olga Blau; Yotaro Ochi; Piroska Klement; Wen-Chien Chou; Igor-Wolfgang Blau; Jih-Luh Tang; Tomasz Zemojtel; Yuichi Shiraishi; Yusuke Shiozawa; Felicitas Thol; Arnold Ganser; Bob Löwenberg; David C Linch; Lars Bullinger; Peter J M Valk; Hwei-Fang Tien; Rosemary E Gale; Seishi Ogawa; Frederik Damm
Journal:  Blood       Date:  2019-01-04       Impact factor: 22.113

2.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

Authors:  Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

3.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

Authors:  N Boissel; H Leroy; B Brethon; N Philippe; S de Botton; A Auvrignon; E Raffoux; T Leblanc; X Thomas; O Hermine; B Quesnel; A Baruchel; G Leverger; H Dombret; C Preudhomme
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

4.  Rad52 inactivation is synthetically lethal with BRCA2 deficiency.

Authors:  Zhihui Feng; Shaun P Scott; Wendy Bussen; Girdhar G Sharma; Gongshe Guo; Tej K Pandita; Simon N Powell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-08       Impact factor: 11.205

5.  Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.

Authors:  Cindy Cavelier; Christine Didier; Naïs Prade; Véronique Mansat-De Mas; Stéphane Manenti; Christian Recher; Cécile Demur; Bernard Ducommun
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

6.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

Review 7.  PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.

Authors:  Patrick G Pilié; Carl M Gay; Lauren A Byers; Mark J O'Connor; Timothy A Yap
Journal:  Clin Cancer Res       Date:  2019-02-13       Impact factor: 12.531

8.  Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Authors:  Margaret Nieborowska-Skorska; Katherine Sullivan; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Grazyna Hoser; Silvia Maifrede; Esteban Martinez; Daniela Di Marcantonio; Elisabeth Bolton-Gillespie; Kimberly Cramer-Morales; Jaewong Lee; Min Li; Artur Slupianek; Daniel Gritsyuk; Sabine Cerny-Reiterer; Ilona Seferynska; Tomasz Stoklosa; Lars Bullinger; Huaqing Zhao; Vera Gorbunova; Katarzyna Piwocka; Peter Valent; Curt I Civin; Markus Muschen; John E Dick; Jean Cy Wang; Smita Bhatia; Ravi Bhatia; Kolja Eppert; Mark D Minden; Stephen M Sykes; Tomasz Skorski
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

9.  Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.

Authors:  Margaret Nieborowska-Skorska; Silvia Maifrede; Yashodhara Dasgupta; Katherine Sullivan; Sylwia Flis; Bac Viet Le; Martyna Solecka; Elizaveta A Belyaeva; Lucia Kubovcakova; Morgan Nawrocki; Martin Kirschner; Huaqing Zhao; Josef T Prchal; Katarzyna Piwocka; Alison R Moliterno; Mariusz Wasik; Steffen Koschmieder; Tony R Green; Radek C Skoda; Tomasz Skorski
Journal:  Blood       Date:  2017-10-17       Impact factor: 25.476

10.  Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.

Authors:  Maria Teresa Esposito; Lu Zhao; Tsz Kan Fung; Jayant K Rane; Amanda Wilson; Nadine Martin; Jesus Gil; Anskar Y Leung; Alan Ashworth; Chi Wai Eric So
Journal:  Nat Med       Date:  2015-11-23       Impact factor: 53.440
View more
  4 in total

Review 1.  t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming.

Authors:  Sophie Kellaway; Paulynn S Chin; Farnaz Barneh; Constanze Bonifer; Olaf Heidenreich
Journal:  Cells       Date:  2020-12-13       Impact factor: 6.600

2.  Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway.

Authors:  Antonella Padella; Maria Chiara Fontana; Giovanni Marconi; Eugenio Fonzi; Elisabetta Petracci; Anna Ferrari; Carmen Baldazzi; Cristina Papayannidis; Andrea Ghelli Luserna Di Rorá; Nicoletta Testoni; Gastone Castellani; Torsten Haferlach; Giovanni Martinelli; Giorgia Simonetti
Journal:  Blood Cancer J       Date:  2021-01-07       Impact factor: 11.037

Review 3.  Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.

Authors:  Antonella Padella; Andrea Ghelli Luserna Di Rorà; Giovanni Marconi; Martina Ghetti; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Hematol Oncol       Date:  2022-01-22       Impact factor: 17.388

Review 4.  AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.

Authors:  Kai Rejeski; Jesús Duque-Afonso; Michael Lübbert
Journal:  Oncogene       Date:  2021-07-30       Impact factor: 9.867
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.